Health Care Equipment

Transtek

Transtek released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 283.74 M, actual EPS CNY 0.1467

Transtek FY2026 Q1 Earnings Release on April 24 After-Market (BJT)

Transtek released FY2025 Annual Earnings on April 9 After-Market (BJT), actual revenue CNY 986.21 M (forecast CNY 1.533 B), actual EPS CNY 0.3764 (forecast CNY 0.36)

Transtek released FY2025 Q4 earnings on April 9 After-Market (BJT), actual revenue CNY 229.08 M, actual EPS CNY 0.0745

Transtek to Release FY2025 Earnings on April 10 After-Market (BJT), Forecast Revenue CNY 1.533 B, EPS CNY 0.36

Transtek released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 235.76 M, actual EPS CNY 0.1074

Transtek released FY2025 9 Months Earnings on October 27 After-Market (BJT), actual revenue CNY 757.13 M, actual EPS CNY 0.3029

Transtek FY2025 Q3 Earnings Release on October 28, After-Market (BJT)

Transtek released FY2025 Semi-Annual earnings on August 15 After-Market (BJT), actual revenue CNY 521.36 M, actual EPS CNY 0.1945

Transtek released FY2025 Q2 earnings on August 15 After-Market BJT, actual revenue CNY 248.06 M, actual EPS CNY 0.0854

Transtek FY2025 Semi-Annual Earning Release on August 16, 2025 (BJT)

Guangdong Leshen Medical Electronics Files New Trademark Applications

Leixin Medical's Subsidiary Rekang Hongye Applies for Extension of Medical Device Registration Certificate

Rui Kang Hong Ye's Dynamic ECG System Medical Device Registration Change Application Accepted

Zhongyoub Securities Research Report Recommends Buying Leyson Medical

Ping An Good Health and Ruili Medical Sign Smart Healthcare Cooperation Agreement

Lekese Medical's Blood Glucose Meter Medical Device Registration Application Accepted

LESHINE MEDICAL reports 67.88% increase in net profit for Q1 2025

Transtek released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 273.31 M, actual EPS CNY 0.11

Transtek to Release FY2025 Q1 Earnings Report on April 26 After-Market BJT

300562

Transtek plans to launch the "Cornerstone No. 1" employee stock ownership plan, with no more than 25 participants, intending to hold no more than 912,200 shares, with a total fundraising cap of 6.9419 million yuan. The duration of the plan is 48 months, with a stock lock-up period of 12 months and 24 months, calculated from the date of approval by the shareholders' meeting

Zhitong

Transtek plans to launch the Cornerstone No. 1 employee stock ownership plan, with a total fundraising amount not exceeding 6.9419 million yuan

According to the Zhitong Finance APP, Transtek disclosed its 2025 stock option incentive plan (draft), which proposes to grant a total of 2 million stock options to 40 incentive recipients, with an exercise price of RMB 15.21 per option. The validity period of this incentive plan is from the date of stock option authorization until all stock options granted to the incentive recipients are exercised or canceled, lasting no more than 36 months

Transtek plans to grant 2 million stock options with an exercise price of RMB 15.21 per share

688130

300793

300903

300003

The blood oxygen monitor sector saw a short-term surge, with SDIC hitting the daily limit, while Cosonic, Transtek, KingShine, Lepu Medical, and KeFu Medical all rose significantly

SDIC

Cosonic

KingShine

Lepu Medical

The blood oxygen monitor sector sees a short-term surge, SDIC hits the limit up

Transtek announced that the company has completed the repurchase and cancellation procedures for 60,000 restricted shares at the Shenzhen branch of China Securities Depository and Clearing Corporation Limited. The repurchase price was 4.97 yuan/share, with a total repurchase amount of 298,200 yuan. After this repurchase and cancellation, the company's total share capital will decrease by 60,000 shares, from 217 million shares to 217 million shares. This repurchase and cancellation will not affect the existing arrangements of the company's 2023 restricted stock incentive plan and will not have a substantial impact on the company's financial condition and operating results

Transtek: Repurchased and canceled 60,000 restricted stocks

Transtek announced that the registration of the arm-type electronic blood pressure monitor medical device applied by the company has been approved. This product consists of a main unit and a cuff, suitable for individuals aged 3 and above with arm circumferences between 15cm and 55cm. It measures blood pressure using the oscillometric method, and the measured data is displayed on a liquid crystal display screen, making the data available for clinical use. The acquisition of this registration certificate will help promote the company's business implementation, strengthen the company's stickiness with customers, enhance the company's market expansion capabilities, and play a positive role in accelerating market development and achieving strategic implementation

Transtek: Arm-type electronic blood pressure monitor obtains Canadian medical device registration certificate

002681

000026

300686

The smart wearable concept has rebounded sharply, with FIYTA hitting the limit up, and Fenda Tech, Longying Precision, CDL, Dongshan Precision, Transtek, and Huanshu Electronics also rising

Fenda Tech

FIYTA

The smart wearable concept experiences a volatile rebound, FIYTA hits the limit up

Transtek's subsidiary Ruikang Hongye has received the "Acceptance Certificate" from the Guangdong Provincial Drug Administration, and its application for the change of the medical device registration certificate for the dynamic electrocardiogram system has been accepted. This change aims to improve product technical requirements to meet the latest industry standards and enhance product competitiveness

Transtek: The change of medical device registration certificate for the holding subsidiary has been accepted

Transtek recently announced that its registered application for the blood glucose meter medical device has been accepted by the Guangdong Provincial Medical Products Administration. This blood glucose meter product consists of a main unit and software, primarily for home use by diabetes patients, capable of detecting glucose concentration in blood samples through in vitro testing to monitor blood sugar control effectiveness. The GBZ41-B model features Bluetooth functionality, allowing measurement results to be uploaded to a designated APP for users to conveniently check their health status

Transtek's medical device registration application for blood glucose meters has been accepted

According to the Zhitong Finance APP, Transtek released its first-quarter report for 2025, with operating revenue of 273 million yuan, a year-on-year increase of 9.90%. The net profit attributable to shareholders of the listed company was 22.942 million yuan, a year-on-year increase of 67.88%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.6489 million yuan, a year-on-year increase of 73.28%. The basic earnings per share were 0.11 yuan

Transtek released its first-quarter performance, with a net profit attributable to the parent company of 22.942 million yuan, an increase of 67.88%

Transtek announced that the medical device registration application for the wrist electronic blood pressure monitor submitted by the company has been approved. This product is suitable for measuring the systolic pressure, diastolic pressure, and pulse rate of adults, with the values provided for diagnostic reference. The model TMB-2285-BT wrist electronic blood pressure monitor features Bluetooth functionality, allowing for real-time transmission of blood pressure measurement data, making it convenient for users to check their health status promptly. The actual sales performance of the above product will depend on future marketing effectiveness, and the company is currently unable to predict its impact on future performance

Transtek: Obtained Medical Device Registration Certificate

Transtek(300562.SZ)